Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia

Blood

Volumn 109, Issue 7, 2007, Pages 2791-2793

  Carpenter, Paul A ^a,b   Snyder, David S ^c   Flowers, Mary E D ^a   Sanders, Jean E ^a,b   Gooley, Theodore A ^a   Martin, Paul J ^a   Appelbaum, Frederick R ^a   Radich, Jerald P ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; EDEMA; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MALE; NAUSEA; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 33947587233     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-019836     Document Type: Article

References (20)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
2. + ALL). Blood. 2006;108:1469-1477.
3. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-466.
4. Radich JP, Olavarria E, Apperly JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:685-702.
5. Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1997;90:1410-1414.
6. Radich JP. Philadelphia chromosome-positive leukemia. Hematol Oncol Clin North Am. 2001;15:21-36.
7. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-1971.
8. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100:1590-1595.
9. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2003;17:1707-1712.
10. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003;9:206-212.
11. Radich, JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632-2638.
12. Sheth SR, Hicks K, Ippoliti C, et al. Safety, tolerability and drug interactions of adjuvant imatinib mesylate (Gleevec) within the first 100 days following stem cell transplantation (SCT) in patients with Ph+ CML and Ph+ ALL at high risk for recurrence. Blood. 2002;100:635a. Abstract 2500.
13. Marin D, Marktel S, Foot N, et al. G-CSF reverses cytopenia and may increase cytogenetic responses in patients with CML treated with imatinib mesylate. Blood. 2002;100:782a. Abstract 3093.
14. Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89:2602-2609.
15. + ALL). Blood. 2005;106:458-463.
16. Anderlini P, Seth S, Hicks K, et al. Re: imatinib mesylate administration in the first 100 days after stem cell transplantation [letter]. Biol Blood Marrow Transplant. 2004;10:883-884.
17. Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK-cell-dependent antitumor effects. J Clin Invest. 2004;114:379-388.
18. Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med. 2006;12:207-213.
19. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006;12:214-219.
20. Smyth MJ. Imatinib mesylate - uncovering a fast track to adaptive immunity. N Engl J Med. 2006;354:2282-2284.